|
ALS in the News
Promising therapy for ALS delivers antisense drug directly to nervous system
Researchers from the University of California, San Diego (UCSD) School of Medicine, the Center for Neurologic Study and Isis Pharmaceutical Corporation have designed and
tested a molecular therapy in animals that they hope will be a major development in the fight to treat amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease.
The study conducted in the laboratory of Don Cleveland, Ph.D., UCSD Professor of Medicine, Neurosciences and Cellular and Molecular Medicine and member of the Ludwig
Institute for Cancer Research, shows that therapeutic molecules known as antisense oligonucleotides can be delivered to the brain and spinal cord through the cerebrospinal fluid (CSF) at doses shown to
slow the progression of ALS in rats. The study will be published July 27 in advance of publication in the August issue of Journal of Clinical Investigation.
With colleagues Timothy Miller, M.D., Ph.D., UCSD Department of Neurosciences, and Richard A. Smith, M.D., of the Center for Neurologic Study, Cleveland found that when
effective doses of the antisense therapy were delivered, far less of a protein that causes a hereditable form of amyotrophic lateral sclerosis was produced.
ALS is a progressive disease that attacks motor neurons that reach from the brain to the spinal cord and from the spinal cord to the muscles throughout the body.
Estimated to affect some 30,000 Americans, most people are diagnosed with ALS between the ages of 40 and 70. Typically, ALS patients live only three to five years after initial diagnosis.
Neurotoxicity from an accumulation of mutant proteins is believed to be at the root of many neurodegenerative diseases. ALS can be caused by a mutation in a protein
called SOD1, and the antisense drug effectively silences the gene that codes for this mutant protein – found in the cells of patients with inherited forms of ALS.
In this disease, selective killing of spinal cord "motor neurons" occurs. Motor neurons are long and complex nerve cells that control voluntary movement.
Degeneration of motor neurons in ALS leads to progressive loss of muscle control, paralysis and untimely death.
Healthy "neighbor" or supporting non-neuronal cells also have a protective effect on damaged mutant motor neurons, slowing the progression of ALS even when the
nerve cells carry the mutant gene. The researchers speculate that the non-neuronal cells play a vital role in nourishing the motor neurons and in scavenging toxins from the cellular environment.
The onset and progression of disease in inherited ALS is determined by the motor neurons and microglia, small immune cells in the spinal cord, which migrate through nerve
tissue and remove damaged cells and debris. Damage to motor neurons determines timing of disease onset. Microglia – the neighborhood, or "helper" cells – are then activated to help
nourish the motor neurons and clean out debris like a vacuum cleaner. But because these neighboring cells are also damaged, they hurt instead of help, thus speeding disease progression.
When the UCSD researchers isolated and shut off mutant SOD1genes in the motor neuron cells only, the disease onset slowed, but the course of the disease eventually caught
up to the control rodents. When mutant genes in only the microglia were silenced, the scientists found almost no effect on disease onset, however the disease progression was significantly slowed.
This discovery – authored by UCSD investigators Severine Boillee, Koji Yamanaka, Cleveland and others and published in the June 2 issue of the journal Science
– confirms the importance of the new therapeutic approach, which delivers an antisense drug directly to the whole nervous system, including non-neuronal cells.
"Limiting mutant damage to microglia robustly slowed the disease's course, even when all motor neurons were expressing high levels of a SOD1 mutant," said
Cleveland. "Our research suggests that what starts ALS and what keeps it going are two separate phases; it also suggests that with the right therapy, ALS could become a manageable, chronic
disease."
Within a year, Cleveland hopes the first clinical trial will be initiated in humans. In order to deliver the antisense drug directly to the nervous system, surgeons will
insert a small pump into a patient using a fairly routine surgery that has already been approved for management of pain. A small catheter is then implanted into the area surrounding the spinal cord, in
order to pump antisense oligonucleotide drugs directly into the nervous system.
The investigators noted that if the antisense approach works for ALS – by delivering therapeutic agents for neurodegenerative diseases across the highly impermeable
blood-brain barrier – it would likely also work in other neurodegenerative conditions, including Alzheimer's, Parkinson's and Huntington's diseases.
"We know we're on target with the pathogenic mechanism," said Cleveland. The remaining question is whether the genetic-based therapy will be tolerated.
"If tolerated, this sets the stage for broader treatment of neurodegenerative disease, especially Huntington's disease, where there is currently no treatment, but key genes involved in promoting
disease are known."
Flight of faith: 3 parishes raise money to send Greenfield man with ALS to Lourdes - Recorder
The Filiaults are planning a trip to Lourdes to pray for Larry s (recovery from ALS, with which he was recently ... diagnosis,' of the ailment more properly called amyotrophic lateral sclerosis, said his wife Maureen ...
Biogen Pays Pretty Price to Expand ALS Pipeline - Seekingalpha.com
The list of unpartnered amyotrophic lateral sclerosis (ALS) treatments just got smaller. Biogen Idec ( BIIB ) has snapped up the phase III-ready neuroprotective drug KNS-760704 for $20m in cash and a $60m ...
Letters: Beliefs vs. actions; ALS families not alone - Everything Alabama Blog
The neurologist was very gentle when he had to drop the bombshell that he believed that she was in the early stages of amyotrophic lateral sclerosis (ALS), better known as Lou Gehrig’s disease. After receiving the ...
Back and Forth: Walk takes a swing at defeating ALS - Post-Bulletin
and two people die from ALS, which stands for Amyotrophic Lateral Sclerosis — more commonly known as Lou Gehrig's disease. Lou Gehrig died of ALS in 1941 following a long and successful professional baseball career.
Ex-Eagle Kevin Turner has ALS - Philadelphia Daily News
Former Eagles fullback Kevin Turner has been diagnosed with amyotrophia lateral sclerosis, more commonly known as Lou Gehrig's disease. The 41-year-old Turner, who played for the Eagles from 1995-99, told ...
Genetic Stutter Increases Risk of ALS - Howard Hughes Medical Institute
The causes of the devastating neurodegenerative disease amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease) are largely mysterious. Five to ten percent of cases are inherited, but most people who ...
Biogen Idec Is Smart to Diversify With New ALS Drug - Minyanville
Biogen Idec ( BIIB ) is known for its multiple sclerosis drugs Tysabri and Avonex, but Carl Icahn's biotech is expanding its neurology practice with a licensing deal with Pittsburgh's Knopp Neurosciences. The ...
IndyCar team rallies around crew member with ALS - AP - msnbc.com
Hall has ALS, a destructive disease without a cure ... Amyotrophic lateral sclerosis — often called Lou Gehrig's Disease, after the baseball star who is believed to have died of it in 1941 — causes degeneration ...
CB grad involved in breakthrough ALS study - msnbc.com
Amyotrophic lateral sclerosis, also called ALS and Lou Gehrig's disease, typically affects older adults and causes brain and spinal cord degeneration. There is no cure and only one drug slows the disease's progression.
|
|
